October 16, 2019, Shanghai--HaiHe Biopharma, a biopharmaceutical company focusing on the discovery, development and commercialization of innovative anti-tumor drugs, announced that the HaiHe Biopharma Production Center has settled down in Taizhou Pharmaceutical High-Tech Zone and that a cooperation agreement has been signed, under which an investment of RMB 600 million yuan shall be made for the first phase of construction of several commercialization manufacture?lines of innovative drugs. Chairman Academician Ding Jian, CEO Dr. Dong Ruiping and senior management team of HaiHe Biopharma attended the signing ceremony. Shi Lijun, Deputy Party Secretary and Mayor of Taizhou, attended and addressed the signing ceremony. The event was presided over by Zhang Xiaobing, a member of the Standing Committee of Taizhou Municipal Party Committee and?Secretary of the Party Working Committee of Taizhou Pharmaceutical High-Tech Zone. The cooperation agreement was signed by Dr. Dong Ruiping and Gu Ping, Deputy Secretary of the Party Working Committee, and Director of the Administrative Committee of Taizhou Pharmaceutical High-Tech Zone as the representatives of both sides.
“With the efficient and orderly marketing of anti-tumor drugs in HaiHe Biopharma’s pipelines, our manufacture?center has settled down in Taizhou, which is an important milestone in the commercial development of HaiHe Biopharma. Taizhou Pharmaceutical High-Tech Zone, which is recognized as one of the important bases of international bio-pharmaceutical innovation, has been exerting its utmost efforts to promote the development of the bio-pharmaceutical industry over the past years and boasts a well-developed industrial chain of innovative drugs. We will work closely with governments at all levels, give full play to HaiHe Biopharma’s science-driven innovation advantages, and continue to comprehensively promote the R&D and commercialization of the Company’s products, so as to deliver safer and more effective innovative drugs to patients by rooting in China and going global,”said Academician Ding Jian, Chairman of HaiHe Biopharma.
“Thanks to the successful construction of Taizhou Pharmaceutical High-Tech Zone focusing on the development of high-end innovative drugs over the years, leading bio-pharma companies such as HaiHe Biopharma are attracted to come and settle down in Taizhou. There’s a saying that human life is of the utmost significance invaluable and when saved with a prescription it will be viewed to be of the greatest morality. This year marks the 70th?anniversary of the founding of the People's Republic of China, while the development of the pharmaceutical cause is the top priority in China’s efforts to build an overall well-off society. HaiHe Biopharma has strong capabilities of research and development of innovative drugs and successful experience. China Medical City will actively cooperate with the development of the enterpriseand provide the enterprise with comprehensive support, so as to accelerate the development of innovative drugs in HaiHe Biopharma.”said Zhang Xiaobing, a member of the Standing Committee of Tiazhou Municipal Party Committee and Secretary of the Party Working Committee of Taizhou Pharmaceutical High-Tech Zone.
Haihe Biopharma focuses on discovery, development and commercialization of innovative anti-tumor drugs. Guided by our mission, “Inclusive and open to diversity, innovation oriented to win together and benefit the mankind”, Haihe Biopharma insists on the way of independent innovation and pursues for global development of Chinese original innovative drugs in partnership with Shanghai Institute of Materia Medica, Chinese Academy of Science (SIMM). The company is led by an academician of the Chinese Academy of Engineering. The senior management team has extensive experiences in drug research and development in China and abroad. Haihe Biopharma has built a precision medical platform guided by biomarkers, and established a fully integrated pre-clinical evaluation technical platform and clinical study system for innovative drugs, with advanced technology and operation in consistence with international standards and norms, covering subunits from compound synthesis, CMC study, biomarker discovery and validation, medical strategy and clinical study, etc. The company has established a globally competitive innovative drug R&D system and robust product pipeline. There are 7 compounds in clinical and 3 compounds in preclinical studies, among which 7 compounds are discovered in-house.
Please visit the company website for more information:?http://www.iacubed.com
Taizhou Pharmaceutical High-Tech Zone (also known as China Medical City) is the first national-level pharmaceutical hi-tech zone ever established in China. After 13 years of construction and development, it has attracted over 1,000 domestic and foreign pharmaceutical companies to come and settle down there, including many world-renowned multinational pharmaceutical companies such as Nestle, AstraZeneca and Boehringer Ingelheim. Such six featured industrial clusters as new chemical preparations, biopharmaceuticals, vaccines, diagnostic reagents, high-end medical equipment, modernization of traditional Chinese medicine and health-promotional products and cosmetics have taken shape over there. High-end innovative drugs represent an advantageous industry that China Medical City strives to develop. In order to promote the rapid development of this industry, China Medical City focuses on improving the industrial chain of innovative drugs development as evidenced by the fact that a number of service platforms tailored for the development of innovative drugs have been built to cover such links as drug discovery, preparation and distribution. Meanwhile, China Medical City is equipped with the most distinctive service team for New Drug Application in China. The clustering of various public carriers and in-depth improvement of comprehensive supporting facilities provide excellent environment and software and hardware guarantee for China Medical City with to build a high-end innovative drug industrial cluster. So far, China Medical City has attracted a large number of innovative pharmaceutical companies represented by AstraZeneca and Fudan-Zhangjiang Bio-Pharmaceutical to come and settle down there.